drugset / Trial / NCT01153919

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

NCT01153919

Phase 2 Terminated 27 enrolled University of Southern California
RandomizedCrossoverDouble-blindTreatment

Summary

RATIONALE: Romiplostim may cause the body to make platelets. PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.

Timeline

Start
2010-06-30
Primary completion
2014-07-14
Completion
2018-07-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Romiplostim Peptide Subcutaneous
Comparator Peginterferon alfa-2a Protein / enzyme biologic Subcutaneous
Comparator Ribavirin Small molecule Oral